MEDI9253 / AstraZeneca - LARVOL DELTA

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ May 2024 | Trial primary completion date: Nov 2024 ➔ May 2024

Combination therapy • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Feb 2025 ➔ Nov 2024 | Trial primary completion date: Feb 2025 ➔ Nov 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CD8 • IL12A

Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors (ESMO-TAT 2023) - P1 | "Administration RP2D of 10 10 with durvalumab was feasible and safe. MEDI9253 infected patients' tumors, and increased CD8 infiltration and PD-L1 expression."

Combination therapy • IO biomarker • Metastases • P1 data • Melanoma • Oncology • Solid Tumor • CD8 • IL12A • PD-L1

First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors (AACR 2022) - P1 | "Secondary objectives include assessing initial efficacy (response and progression-free survival by RECIST v1.1, and overall survival), pharmacodynamics in the TME, immunogenicity, and pharmacokinetics (viremia and IL-12). The trial is recruiting."

Clinical • Combination therapy • IO biomarker • Oncolytic virus • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • IL12A

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | N=86 ➔ 37 | Trial completion date: Nov 2025 ➔ Feb 2025 | Trial primary completion date: Nov 2025 ➔ Feb 2025

Combination therapy • Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CD8 • IL12A

"Another IL-12 bites the dust - MEDI9253 $AZN gene therapy https://t.co/1UBVtcjXcv" (@JacobPlieth)

Gene therapy • Gene Therapies • IL12A

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov) - P1; N=86; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting; Trial completion date: Jun 2025 ➔ Nov 2025; Trial primary completion date: Jun 2025 ➔ Nov 2025

Clinical • Combination therapy • Enrollment open • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov) - P1; N=86; Not yet recruiting; Sponsor: AstraZeneca

Clinical • Combination therapy • New P1 trial • Oncology • Solid Tumor